MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/icvts/ivab065

Медицинская библиотека · Interactive cardiovascular and thoracic surgery · 2021

Balloon-expanding transcatheter aortic valve implantation for degenerated Mitroflow bioprostheses: clinical and echocardiographic long-term outcomes.

Hernández José M, Suquía Begoña, Queizan José A, Fisac Rosa M, Sanchez José J, Fernández-Calvo Francisco J, García-Sanz Ramón, Olivier Carmen, Bárez Abelardo, Calmuntia María J, García-Frade Javier, Portero Juan A, López Rosa, Aguilera Carmen, Navajo Jose A, San-Miguel Jesús F

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

This study aims to analyse the risks associated with valve-in-valve procedures for treating structural valve deterioration in Mitroflow bioprostheses, as well as to determine the impact of the original Mitroflow size on the patients' long-term outcomes.

METHODS

Between January 2012 and September 2019, 21 patients (61.9% males; mean age 82.4 ± 5.4 years) were treated for Mitroflow deterioration with valve-in-valve procedures (12 transapical and 9 transfemoral).

RESULTS

Mean EuroSCORE I and EuroSCORE II were 28.2% ± 13.6% and 10.5% ± 6.1%, respectively. Six patients presented an indexed aortic root diameter <14 mm/m2 and 7 patients a diameter of sinus of Valsalva <30 mm. Implanted transcatheter valve sizes were 20 mm in 6 cases, 23 mm in 14 cases and 26 mm in 1 patient. A Valve Academic Research Consortium-2 complication occurred in 23.8% of cases, including 3 coronary occlusions. In-hospital mortality was 9.5%. The 20 mm transcatheter valves presented significantly higher postoperative peak and mean aortic gradients than other sizes (54.1 ± 11.3 mmHg vs 29.9 ± 9.6 mmHg, P = 0.003; and 29.3 ± 7.7 mmHg vs 17.4 ± 5.9 mmHg, P = 0.015, respectively). There were 12 cases of patient-prosthesis mismatch (57.1%) and 3 cases (14.3%) of severe patient-prosthesis mismatch. Cumulative survival was 85.7% ± 7.6% at 1 year, 74.3% ± 10% at 2 years and 37.1% ± 14.1% at 5 years.

CONCLUSIONS

Valve-in-valve procedures with balloon-expandable transcatheter valves associate a high risk of coronary occlusion in patients with indexed aortic root diameter <14 mm/m2 and low coronary ostia <12 mm. Valve-in valve procedures with 20 mm balloon-expandable transcatheter valves in ≤21 mm Mitroflow bioprosthesis leave significant residual transvalvular gradients that might obscure patients' long-term outcomes.

Для цитирования: Hernández José M, Suquía Begoña, Queizan José A, Fisac Rosa M, Sanchez José J, Fernández-Calvo Francisco J, García-Sanz Ramón, Olivier Carmen, Bárez Abelardo, Calmuntia María J, García-Frade Javier, Portero Juan A, López Rosa, Aguilera Carmen, Navajo Jose A, San-Miguel Jesús F. Balloon-expanding transcatheter aortic valve implantation for degenerated Mitroflow bioprostheses: clinical and echocardiographic long-term outcomes.. Interactive cardiovascular and thoracic surgery. 2021. DOI: 10.1093/icvts/ivab065.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.